Menu

Life Sciences & Healthcare

PEM Corporate Finance has wide-ranging experience advising businesses in the UK life sciences and healthcare sector. Please get in touch for an informal and confidential chat about your plans.

In the heart of the Cambridge life sciences & healthcare cluster

Cambridge is recognised for its strength in education, innovation and R&D. Located in one of the largest life sciences and healthcare clusters in the UK, PEM Corporate Finance are ideally placed to advise businesses and investors navigating the Cambridge M&A market.

This sector of knowledge-intensive industries consists of a wide range of areas such as pharmaceuticals, medical devices, medical robotics, AI/machine learning and biotechnology. Cambridge and the region have a sophisticated supply chain in place to support R&D and manufacturing.

There are 6,330 businesses in the UK life sciences and healthcare sector, employing 268,000 people and generating turnover of £88.9bn (2020).

Transaction trends

Total deal volume for UK life sciences and healthcare transactions valued at less than £100m has on average grown at a rate c.20% each year from 2020-2022, total deal value has also grown on average c.13% each year. Total deal value grew from c.£610m in 2020 to c.£780m, whilst total deal volume has risen from 80 deals in 2020 to 116 deals.

Regulatory changes have also been a major driver of M&A activity in the UK healthcare industry. The recent changes in healthcare policies, such as the move towards integrated care systems, have encouraged healthcare providers to restructure their operations and consolidate their services. These regulatory changes have also opened up new opportunities for M&A activity, such as the acquisition of digital health companies and other innovative start-ups.

Technological advancements have also played a significant role in driving M&A activity. Many healthcare providers are seeking to acquire companies that offer new and innovative technologies to improve patient outcomes and reduce costs. This has led to a number of industry adjacent deals, with healthcare providers acquiring businesses in industries such as medical devices, pharmaceuticals, and digital health.

Our life sciences & healthcare experience

PEM Corporate Finance has strong credentials when it comes to M&A, buyouts, or valuing companies in the life sciences and healthcare space. Recent transaction highlights include: The sale of Cambridge Bioscience, the sale of MJog, the sale of Medical Device Usability, the sale of Pope Woodhead & Associates, the sale of Modular Dimensions, and the sale of Nitrex.

Below are some life science and healthcare sector deals we have advised:

"Having PEM Corporate Finance in negotiations was extremely valuable."
Anthony Savill, former CEO, Molecular Dimensions Ltd
"PEM Corporate Finance helped us with our original management buyout and later with an acquisition. Our expectations were met 100%. The team are very straightforward, honest and insightful. Fantastic service."
Dr Mike Macnamme, CEO, Bourn Hall Ltd
"They brought three or four buyers to the table for us, which helped us get a good price. Lake and Tony are not stuffy accountants, far from it! They are very commercial."
Steve Roberts, Commercial Director, Essex Medical + Forensic Ltd